We provide a comprehensive GPCR catalog covering 550 receptors, including 300 human and 250 mouse GPCRs. Using our proprietary high-sensitivity assay technology, receptor activity can be evaluated in a unified format, supporting panel assays, dose-response studies, and a wide range of functional analyses. Our platform enables comprehensive characterization, including orphan GPCRs. Click below for details or contact us for information about GPCRs of other animal species such as rats, rabbits, dogs, and macaque monkeys.
Filters Sort results
Reset Apply
Species | Receptor | Family | Assays | |
|---|---|---|---|---|
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: serotonin EC50: 13 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ à la carte |  Reference agonist: serotonin EC50: 4.0 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: serotonin EC50: 2.7 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: serotonin EC50: 3.2 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: serotonin EC50: 3.3 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: serotonin EC50: 1.9 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Ophthalmology ⋅ Cardiology ⋅ à la carte |  Reference agonist: serotonin EC50: 2.5 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: serotonin EC50: 1.7 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ à la carte |  Reference agonist: serotonin EC50: 26 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ Cardiology ⋅ à la carte |  Reference agonist: serotonin EC50: 85 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ à la carte |  Reference agonist: serotonin EC50: 8.6 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: serotonin EC50: 1.8 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: carbachol EC50: 310 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Cardiology ⋅ à la carte |  Reference agonist: carbachol EC50: 110 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Ophthalmology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: carbachol EC50: 31 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: carbachol EC50: 47 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: carbachol EC50: 5.9 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Psychiatry ⋅ Neurology ⋅ Cardiology ⋅ Respiratory ⋅ à la carte |  Reference agonist: NECA EC50: 4.8 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Hematology ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: NECA EC50: 11 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: NECA EC50: 19 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: NECA EC50: 1.6 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Cardiology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: L‐phenylephrine EC50: 18 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: L‐phenylephrine EC50: 28 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Hematology ⋅ Cardiology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: L‐phenylephrine EC50: 67 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: noradrenaline EC50: 71 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Cardiology ⋅ à la carte |  Reference agonist: noradrenaline EC50: 33 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ Cardiology ⋅ à la carte |  Reference agonist: noradrenaline EC50: 89 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: isoproterenol EC50: 22 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: isoproterenol EC50: 26 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Cardiology ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: isoproterenol EC50: 47 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: angiotensin ⅠⅠ EC50: 920 pM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: apelin‐13 EC50: 8.1 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: TGR5 agonist EC50: 350 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: bombesin EC50: 2.4 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Gastrointestinal ⋅ Dermatology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: GRP EC50: 1.3 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: NMB EC50: 590 pM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: calcitonin EC50: 2.7 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Hematology ⋅ à la carte |  Reference agonist: CGRP EC50: 1.0 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: cinacalcet EC50: 140 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CP55940 EC50: 640 pM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CP55940 EC50: 2.6 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: LPI EC50: 1.2 µM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ à la carte |  Reference agonist: N‐oleoylethanolamine EC50: 6.3 µM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: chemerin EC50: 15 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CCL3 EC50: 250 pM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CCL2 EC50: 1.3 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Ophthalmology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CCL22 EC50: 20 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CCL4 EC50: 7.1 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Ophthalmology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CCL20 EC50: 3.8 nM | ||
| Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CCL21 EC50: 15 nM |
Contact Us
For quotation requests or inquiries about our assay services, custom assay development, co-development opportunities, or other topics, please use the contact form or email us at [email protected]. We also support GPCR assays across a wide range of animal species, including rats, rabbits, dogs, and cynomolgus macaques. Our team will respond within 24 hours.
Ordering Process
Service flow chart
Request a Quotation
Tell us about your study goals. We’ll review your project outline and propose a customized experiment plan. We’re happy to sign a non-disclosure agreement (NDA) upon request to ensure confidentiality.
STEP
1
Confirm and Ship Your Order
Once you approve the quotation, you can place the order. Please ship your compounds to our lab under DDP (Delivery Duty Paid) terms. We accept payment via bank transfer.
STEP
2
Study in Progress
We begin the study based on the agreed design. Typical turnaround time is as short as three weeks, depending on project complexity and current scheduling. We’ll keep you informed of progress or any unforeseen delays.
STEP
3
Receive Results
You’ll receive a comprehensive study report (PDF) along with the raw data (Excel format). We’re available to answer questions and support your data interpretation.
STEP
4